Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Clinical Research of Mesylate Apatinib Combined With Docetaxel and S-1 as the First-line Treatment of Metastatic Gastric Cancer

NCT03154983 is registered in ClinicalTrials.gov with Zhou Fuxiang as lead sponsor.

NCT NCT03154983
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03154983 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Clinical Research of Mesylate Apatinib Combined With Docetaxel and S-1 as the First-line Treatment of Metastatic Gastric Cancer
Lead sponsor
Zhou Fuxiang
Phase
Phase 2
Overall status
Unknown status
Start date
May 20, 2017
Completion date
December 31, 2021
Enrollment
48 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic gastric cancer